Skip to main content
SpringerLink
Log in

A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dhainaut JF, Laterre PF, LaRosa SP, Levy H, Garber GE, Heiselman DO, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, Maki D (2003) The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology and results. Crit Care Med 31:2291–301

    Article  CAS  PubMed  Google Scholar 

  2. Sprung CL, Finch RG, Thijs LG, Glauser MP (1996) International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med 24:1441–1447

    Article  CAS  PubMed  Google Scholar 

  3. Dhainaut JF, Tenaillon A, Hemmer M, Damas P, Le Tulzo Y, Radermacher P, Schaller MD, Sollet JP, Wolff M, Holzapfel L, Zeni F, Vedrinne JM, de Vathaire F, Gourlay ML, Guinot P, Mira JP (1998) Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 26:1963–1971

    Google Scholar 

  4. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fischer CJ Jr (2001) Recombinant human protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept of Intensive Care and Emergency Medicine, Cochin Hospital, AP-HP, University of Paris 5, 27 rue du Faubourg St Jacques, 75679, Paris Cedex 14, France

    J. F. Dhainaut

  2. Lilly Research Laboratories, DC0522, 307 E McCarty Street, Indianapolis, IN 46285, USA

    W. L. Macias & D. R. Nelson

Authors
  1. J. F. Dhainaut
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. L. Macias
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. R. Nelson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. F. Dhainaut.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dhainaut, J.F., Macias, W.L. & Nelson, D.R. A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker. Intensive Care Med 30, 995 (2004). https://doi.org/10.1007/s00134-004-2246-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-004-2246-0

Keywords

Search

Navigation